Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note released on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 0.4 %

NASDAQ:AKTX opened at $1.21 on Monday. The firm’s fifty day moving average price is $1.39 and its two-hundred day moving average price is $2.58. Akari Therapeutics has a one year low of $0.90 and a one year high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.